These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32071673)

  • 1. BRM Targeting Compounds for the Potential Treatment of Cancer.
    Kargbo RB
    ACS Med Chem Lett; 2020 Feb; 11(2):99-100. PubMed ID: 32071673
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy.
    Gramling S; Rogers C; Liu G; Reisman D
    Oncogene; 2011 Jul; 30(29):3289-94. PubMed ID: 21478905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling.
    Zhang Z; Wang F; Du C; Guo H; Ma L; Liu X; Kornmann M; Tian X; Yang Y
    Cancer Lett; 2017 Aug; 402():213-224. PubMed ID: 28602977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chromatin remodeling protein BRM regulates the transcription of tight junction proteins: Implication in breast cancer metastasis.
    Yang Y; Liu L; Fang M; Bai H; Xu Y
    Biochim Biophys Acta Gene Regul Mech; 2019 May; 1862(5):547-556. PubMed ID: 30946989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROTACs Targeting BRM (SMARCA2) Afford Selective
    Berlin M; Cantley J; Bookbinder M; Bortolon E; Broccatelli F; Cadelina G; Chan EW; Chen H; Chen X; Cheng Y; Cheung TK; Davenport K; DiNicola D; Gordon D; Hamman BD; Harbin A; Haskell R; He M; Hole AJ; Januario T; Kerry PS; Koenig SG; Li L; Merchant M; Pérez-Dorado I; Pizzano J; Quinn C; Rose CM; Rousseau E; Soto L; Staben LR; Sun H; Tian Q; Wang J; Wang W; Ye CS; Ye X; Zhang P; Zhou Y; Yauch R; Dragovich PS
    J Med Chem; 2024 Jan; 67(2):1262-1313. PubMed ID: 38180485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancers.
    Rago F; DiMare MT; Elliott G; Ruddy DA; Sovath S; Kerr G; Bhang HC; Jagani Z
    Biochem Biophys Res Commun; 2019 Jan; 508(1):109-116. PubMed ID: 30527810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of BRM Sensitizes
    Zernickel E; Sak A; Riaz A; Klein D; Groneberg M; Stuschke M
    Mol Cancer Ther; 2019 Mar; 18(3):656-666. PubMed ID: 30478150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRM: the core ATPase subunit of SWI/SNF chromatin-remodelling complex-a tumour suppressor or tumour-promoting factor?
    Jancewicz I; Siedlecki JA; Sarnowski TJ; Sarnowska E
    Epigenetics Chromatin; 2019 Nov; 12(1):68. PubMed ID: 31722744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Patterns and Outcomes of Women with Symptomatic and Asymptomatic Breast Cancer Brain Metastases: A Single-Center Retrospective Study.
    Gao YK; Kuksis M; Id Said B; Chehade R; Kiss A; Tran W; Sickandar F; Sahgal A; Warner E; Soliman H; Jerzak KJ
    Oncologist; 2021 Nov; 26(11):e1951-e1961. PubMed ID: 34506676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Rates of Brain Metastases and Association With Breast Cancer Subtypes in Ontario, Canada.
    Wang XY; Rosen MN; Chehade R; Sahgal A; Das S; Warner E; Saskin R; Zhang B; Soliman H; Chan KKW; Jerzak KJ
    JAMA Netw Open; 2022 Aug; 5(8):e2225424. PubMed ID: 35960523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer.
    Moraes FY; Mansouri A; Dasgupta A; Ramotar M; Kosyak N; Weiss J; Laperriere N; Millar BA; Berlin A; Conrad T; van Prooijen M; Heaton R; Coolens C; Winter J; Bernstein M; Zadeh G; Kongkham P; Doherty M; Shultz DB
    Lung Cancer; 2021 May; 155():34-39. PubMed ID: 33721614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen Receptor Is Expressed in the Majority of Breast Cancer Brain Metastases and Is Subtype-Dependent.
    Fan KY; Chehade R; Qazi M; Moravan V; Nofech-Mozes S; Jerzak KJ
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical treatment of brain metastases from solid tumours.
    Cappuzzo F; Mazzoni F; Maestri A; Di Stefano A; Calandri C; Crino L
    Forum (Genova); 2000; 10(2):137-48. PubMed ID: 10875975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression in breast cancer brain metastases.
    Chehade R; Qazi MA; Ennis M; Sahgal A; Das S; Nofech-Mozes S; Jerzak KJ
    Neurooncol Adv; 2022; 4(1):vdac154. PubMed ID: 36299795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concerted genomic targeting of H3K27 demethylase REF6 and chromatin-remodeling ATPase BRM in Arabidopsis.
    Li C; Gu L; Gao L; Chen C; Wei CQ; Qiu Q; Chien CW; Wang S; Jiang L; Ai LF; Chen CY; Yang S; Nguyen V; Qi Y; Snyder MP; Burlingame AL; Kohalmi SE; Huang S; Cao X; Wang ZY; Wu K; Chen X; Cui Y
    Nat Genet; 2016 Jun; 48(6):687-93. PubMed ID: 27111034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.
    Varešlija D; Priedigkeit N; Fagan A; Purcell S; Cosgrove N; O'Halloran PJ; Ward E; Cocchiglia S; Hartmaier R; Castro CA; Zhu L; Tseng GC; Lucas PC; Puhalla SL; Brufsky AM; Hamilton RL; Mathew A; Leone JP; Basudan A; Hudson L; Dwyer R; Das S; O'Connor DP; Buckley PG; Farrell M; Hill ADK; Oesterreich S; Lee AV; Young LS
    J Natl Cancer Inst; 2019 Apr; 111(4):388-398. PubMed ID: 29961873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRG1 and BRM function antagonistically with c-MYC in adult cardiomyocytes to regulate conduction and contractility.
    Willis MS; Holley DW; Wang Z; Chen X; Quintana M; Jensen BC; Tannu M; Parker J; Jeyaraj D; Jain MK; Wolfram JA; Lee HG; Bultman SJ
    J Mol Cell Cardiol; 2017 Apr; 105():99-109. PubMed ID: 28232072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419.
    Routh ED; Van Swearingen AED; Sambade MJ; Vensko S; McClure MB; Woodcock MG; Chai S; Cuaboy LA; Wheless A; Garrett A; Carey LA; Hoyle AP; Parker JS; Vincent BG; Anders CK
    Front Oncol; 2022; 12():818693. PubMed ID: 35992833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying targets for the restoration and reactivation of BRM.
    Kahali B; Gramling SJ; Marquez SB; Thompson K; Lu L; Reisman D
    Oncogene; 2014 Jan; 33(5):653-64. PubMed ID: 23524580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state.
    Yamamichi N; Inada K; Ichinose M; Yamamichi-Nishina M; Mizutani T; Watanabe H; Shiogama K; Fujishiro M; Okazaki T; Yahagi N; Haraguchi T; Fujita S; Tsutsumi Y; Omata M; Iba H
    Cancer Res; 2007 Nov; 67(22):10727-35. PubMed ID: 18006815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.